GMED · XBRL financial data

Globus Medical financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (GMED's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	789	958	1,023	1,568	2,519	2,939
Cost of goods and services sold	217	239	264	548	1,035	958
Gross profit	572	719	759	1,020	—	—
Research and development	85	97	73	124	164	147
Selling, general and administrative	355	408	432	643	981	1,178
Total operating expenses	460	547	531	887	—	—
Operating income (loss)	111	172	228	133	166	480
Other income (expense)	14	8	15	32	2	3
Income tax expense (benefit)	24	31	53	43	18	67
Net income (loss)	102	149	190	123	103	538
Earnings per share, basic USD per share	1.04	1.48	1.89	1.09	0.76	3.98
Earnings per share, diluted USD per share	1.01	1.44	1.85	1.07	0.75	3.92
Weighted average shares, basic millions of shares	99	101	100	113	136	135
Weighted average shares, diluted millions of shares	101	104	103	115	138	137

Fiscal years (GMED's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	239	193	150	467	784	526
Marketable securities	187	250	296	50	106	31
Marketable securities, non-current	359	562	496	75	66	72
Accounts receivable	142	164	213	503	558	679
Inventory	229	237	299	848	659	759
Prepaid and other current assets	18	18	21	45	50	65
Total current assets	822	865	983	1,915	2,177	2,126
Property and equipment, net	217	221	244	587	562	564
Right-of-use asset	5	5	6	60	50	64
Goodwill	157	180	197	1,435	1,432	1,435
Total assets	1,679	1,957	2,076	5,086	5,252	5,303
Accounts payable	18	22	36	57	75	99
Accrued liabilities	78	91	95	240	261	334
Total current liabilities	121	140	159	392	856	498
Lease liability, non-current	3	3	3	91	84	104
Total liabilities	173	216	230	1,088	1,074	730
Retained earnings	1,045	1,194	1,240	1,137	1,153	1,388
Total stockholders' equity	1,506	1,741	1,846	3,998	4,177	4,573
Total liabilities and equity	1,679	1,957	2,076	5,086	5,252	5,303
Common shares outstanding (cover page) millions of shares	100	102	100	135	138	135

Fiscal years (GMED's year ends in late December)

In millions of dollars	FY 2020Dec 31, 2020	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	102	149	190	123	103	538
Stock-based compensation	27	31	33	53	54	50
Depreciation and amortization	63	70	68	145	254	277
Net cash from operating activities	199	276	178	243	521	753
Purchases of property and equipment	64	57	74	78	115	165
Net cash from investing activities	(117)	(376)	(110)	303	(176)	(355)
Share repurchases	105	—	144	226	86	300
Net cash from financing activities	(39)	54	(110)	(232)	(28)	(679)
Net change in cash	44	(46)	(43)	317	317	(258)

SIC 3841 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 3841 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.

Company	Cash ($M)	Revenue, quarter ($M)	Operating cash flow, quarter ($M)	Shares outstanding	Runway	Quarter
Globus Medical	508	790	210*	134.3M	—	Q2 FY26 10-QJun 30, 2026
MSA Safety	187	536	82*	38.5M	—	Q3 FY26 10-QSep 30, 2026
MiniMed Group	207	843	(49)	281.3M	2.3 quarters	Q1 FY27 10-QJul 31, 2026
GLAUKOS	162	211	39*	59.2M	—	Q3 FY26 10-QSep 30, 2026
Merit Medical Systems	504	416	65*	59.9M	—	Q3 FY26 10-QSep 30, 2026
iRhythm Holdings	247	224	51*	33.0M	—	Q2 FY26 10-QJun 30, 2026
Penumbra	254	410	42*	39.4M	—	Q3 FY26 10-QSep 30, 2026
TransMedics Group	491	190	17*	34.7M	—	Q2 FY26 10-QJun 30, 2026
Integer Holdings	14	450	37*	34.0M	—	Q3 FY26 10-QOct 2, 2026

Not investment advice. Not affiliated with the U.S. SEC.